PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

被引：0

作者：

McDonald, F. ^{[1
]}

Mornex, F. ^{[2
]}

Garassino, M. C. ^{[3
]}

Filippi, A. R. ^{[4
,5
]}

Christoph, D. ^{[6
]}

Haakensen, V. D. ^{[7
]}

Agbarya, A. ^{[8
]}

Van den Heuvel, M. ^{[9
]}

Vercauter, P. ^{[10
]}

Chouaid, C. ^{[11
]}

Pichon, E. ^{[12
]}

Siva, S. ^{[13
]}

Steinbusch, L. ^{[9
]}

Peretz, I. ^{[14
]}

Solomon, B. ^{[15
]}

Decoster, L. ^{[16
]}

Sawyer, W. ^{[17
]}

Allen, A. ^{[18
]}

Licour, M. ^{[19
]}

Girard, N. ^{[20
,21
]}

机构：

[1] Royal Marsden Hosp NHS Fdn Trust, Lung Unit, London, England

[2] Ctr Hosp Univ Lyon, Dept Radiat Oncol, Lyon, France

[3] Ist Nazl Tumori Milano Fdn IRCCS, Div Med Oncol, Milan, Italy

[4] Fdn IRCCS Policlin San Matteo, Dept Radiat Oncol, Pavia, Italy

[5] Univ Pavia, Pavia, Italy

[6] Evangel Kliniken Essen Mitte, Dept Med Oncol, Evangel Huyssens Stiftung, Essen, Germany

[7] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[8] Bney Zion Med Ctr, Dept Oncol, Haifa, Israel

[9] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[10] Onze Lieve Vrouw Ziekenhuis Aalst, Dept Pneumol, Aalst, Belgium

[11] CHI Creteil, Serv Pneumol, Creteil, France

[12] CHRU Tours, Serv Pneumol, Hop Bretonneau, Tours, France

[13] Sir Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Australia

[14] Clalit Hlth Serv, Inst Oncol, Tel Aviv, Israel

[15] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia

[16] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Med Oncol, Brussels, Belgium

[17] AstraZeneca, Cambridge, England

[18] AstraZeneca, Gaithersburg, MD USA

[19] Astrazeneca, Paris, France

[20] Inst Curie, Inst Thorax, Paris, France

[21] Montsouris, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

79MO

引用

页码：S738 / S739

页数：2

共 50 条

[1] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
Girard, N.
Mornex, F.
Christoph, D. C.
Fietkau, R.
Filippi, A. R.
Field, J.
Garrido Lopez, P.
McDonald, F.
Peters, S.
Klein, A. B.
Licour, M.
Garassino, M. C.
ANNALS OF ONCOLOGY, 2019, 30
[2] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
Christoph, D. C.
Behringer, D.
Emde, T. O.
Goekkurt, E.
Laack, E.
Mueller-Huesmann, H.
Schuett, P.
Schumann, C.
Seese, B.
Fietkau, R.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 212 - 212
[3] Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFRMutated NSCLC (PACIFIC-R)
Peters, S.
Christoph, D. C.
Field, J. K.
Fietkau, R.
Filippi, A. R.
Garassino, M.
Garrido, P.
McDonald, F.
Mornex, F.
Markman, B.
Solomon, B. J.
Anand, S.
Chander, P.
Qiao, Y.
Girard, N.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S83 - S83
[4] Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study
Zhao, Binghao
Li, Huanzhang
Ma, Wenbin
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : e38 - e39
[5] Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
Filippi, A. R.
Bar, J.
Chouaid, C.
Christoph, D. C.
Field, J. K.
Fietkau, R.
Garassino, M. C.
Garrido, P.
Haakensen, V. D.
Kao, S.
Markman, B.
Mcdonald, F.
Mornex, F.
Moskovitz, M.
Peters, S.
Sibille, A.
Siva, S.
Heuvel, M. van den
Vercauter, P.
Anand, S.
Chander, P.
Licour, M.
Lima, A. R. de
Qiao, Y.
Girard, N.
ESMO OPEN, 2024, 9 (06)
[6] PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Girard, N.
Smit, H. J. M.
Sibille, A.
McDonald, F.
Mornex, F.
Garassino, M. C. C.
Filippi, A. R.
Peters, S.
Field, J. K.
Christoph, D. C.
Fietkau, R.
Haakensen, V. D.
Bar, J.
Chouaid, C.
Bray, V.
Kao, S.
Sawyer, W.
Allen, A.
Licour, M.
Garrido, P.
ANNALS OF ONCOLOGY, 2021, 32 : S939 - S940
[7] Pacific-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy
Christoph, Daniel
Girard, N.
Smit, H. J. M.
Sibille, A.
Mcdonald, F.
Mornex, F.
Garassino, M. C.
Filippi, A. R.
Peters, S.
Field, J. K.
Haakensen, V. Drageset
Bar, J.
Chouaid, C.
Bray, V.
Kao, S.
Sawyer, W.
Allen, A.
Licour, M.
Garrido, P.
Fietkau, R.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 151 - 151
[8] Pacific-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with Durvalumab after chemoradiotherapy
Christoph, D. C.
Girard, N.
Smit, H. J. M.
Sibille, A.
McDonald, F.
Mornex, F.
Garassino, M. C.
Filippi, A. R.
Peters, S.
Field, J. K.
Haakensen, Drageset, V
Bar, J.
Chouaid, C.
Bray, V
Kao, S.
Sawyer, W.
Allen, A.
Licour, M.
Garrido, P.
Fietkau, R.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 53 - 53
[9] Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
Park, Cheol-Kyu
Oh, Hyung-Joo
Kim, Young-Chul
Kim, Yong-Hyub
Ahn, Sung-Ja
Jeong, Won Gi
Lee, Jeong Yeop
Lee, Jae Cheol
Choi, Chang Min
Ji, Wonjun
Song, Si Yeol
Choi, Juwhan
Lee, Sung Yong
Kim, Hakyoung
Lee, Shin Yup
Park, Jongmoo
Yoon, Seong Hoon
Joo, Ji Hyeon
Oh, In-Jae
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1042 - 1054
[10] Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Girard, N.
Fietkau, R.
Garassino, M.
Garrido, P.
Field, J. K.
Peters, S.
Smit, H. J. M.
Perol, M.
Merle, P.
Sibille, A.
Markman, B.
Bouchaab, H.
Moskovitz, M.
Schumann, C.
Gregorc, V.
Klein, A. B.
Perez, I. Diaz
Sawyer, W.
Licour, M.
Christoph, D.
ANNALS OF ONCOLOGY, 2020, 31 : S805 - S806

← 1 2 3 4 5 →